Kalaris Therapeutics
KLRSKalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with significant unmet medical needs.
Earnings
Next report
Nov 11, 2026 (in 2 months)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with significant unmet medical needs. The company's lead product candidate is TH103, a novel anti-VEGF decoy receptor engineered for extended intraocular retention and enhanced inhibition of vascular endothelial growth factor. Their core value proposition centers on reducing the treatment burden for patients by providing longer-acting therapies for neovascular retinal conditions.
Clinical-stage developer challenging market leaders with a differentiated molecular design intended to offer superior durability and reduced injection frequency.
FAQ
- What is Kalaris Therapeutics's market cap?
- Kalaris Therapeutics (KLRS) has a market capitalization of $75.7M and trades on NASDAQ.
- Who are Kalaris Therapeutics's competitors?
- Kalaris Therapeutics's key competitors include Kodiak Sciences, Inc., 4D Molecular Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
- Who does Kalaris Therapeutics partner with?
- Kalaris Therapeutics's notable partners include Regents of the University of California, STC Biologics, Inc., Sharp Sterile Manufacturing, and others.
- What subsidiaries does Kalaris Therapeutics have?
- Kalaris Therapeutics's subsidiaries include Legacy Kalaris.
- Where is Kalaris Therapeutics headquartered?
- Kalaris Therapeutics is headquartered in United States of America. It has been publicly traded since 2025.